Scholar Rock Secures $311.8M in New Capital, Extends Runway into 2027, and Advances Lead SMA Candidate with FDA BLA Resubmission Acceptance

summarizeSummary

Scholar Rock Holding Corp reported increased Q1 2026 net loss but significantly strengthened its financial position by securing over $300 million in new capital, extending its cash runway into 2027, and achieving FDA acceptance for its apitegromab BLA resubmission.

check_boxKey Events

• Q1 2026 Financial Results

  The company reported a net loss of $105.5 million for the three months ended March 31, 2026, compared to $74.7 million for the same period in 2025. Basic and diluted net loss per share was ($0.83) for Q1 2026, up from ($0.67) in Q1 2025, reflecting increased R&D and G&A expenses.

• Significant Capital Raise and Debt Refinancing

  Scholar Rock secured $200 million from a new debt facility with Blue Owl Capital and raised $111.8 million through an At-The-Market (ATM) offering during Q1 2026. This financing included repaying $103.7 million of existing debt, resulting in a $3.3 million loss on extinguishment of debt.

• Extended Cash Runway

  As of March 31, 2026, the company held $479.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2027. An additional $150 million from the Blue Owl debt facility is available upon FDA approval of apitegromab.

• Apitegromab BLA Resubmission Accepted

  The Biologics License Application (BLA) for apitegromab for Spinal Muscular Atrophy (SMA) was resubmitted in March 2026 with two fill-finish facilities and accepted by the FDA, setting a Prescription Drug User Fee Act (PDUFA) action date of September 30, 2026. This follows a Complete Response Letter in September 2025 related to a third-party facility inspection.

auto_awesomeAnalysis

Scholar Rock Holding Corp reported a significant increase in its net loss for Q1 2026, driven by higher research and development and general and administrative expenses as it progresses its pipeline and builds commercial infrastructure. However, this filing highlights substantial positive developments in financing and regulatory progress. The company successfully secured $200 million from a new debt facility and raised $111.8 million through an At-The-Market (ATM) offering, significantly boosting its liquidity and extending its cash runway into 2027. Critically, the Biologics License Application (BLA) for its lead candidate, apitegromab for SMA, was resubmitted and accepted by the FDA with a PDUFA date of September 30, 2026, a key step forward after a prior Complete Response Letter. This capital infusion and regulatory progress are vital for a life sciences company nearing potential commercialization, providing financial stability and a clear path for its lead product.